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Abstract
Drug allergies occur when hapten-like drug metabolites conjugated to serum proteins, through 
their interactions with specific immunoglobulin E (IgE), trigger allergic reactions that can be life-
threatening. A molecule termed covalent heterobivalent inhibitor (cHBI) was designed to 
specifically target drug-hapten specific IgE to prevent it from binding drug-haptenated serum 
proteins. cHBI binds the two independent sites on a drug-hapten specific antibody and covalently 
conjugates only to the specific IgE, permanently inhibiting it. The cHBI design was evaluated via 
ELISA to measure cHBI-IgE binding, degranulation assays of rat basophil leukemia (RBL) cells 
for in vitro efficacy, and mouse models of ear swelling and systemic anaphylaxis responses for in 
vivo efficacy. The cHBI design was evaluated using two seperate models: one specific to inhibit 
penicillin G reactive IgE, and another to inhibit IgE specific to a model compound, dansyl. We 
show that cHBI conjugated specifically to its target antibody and inhibited degranulation in 
cellular degranulation assays using RBL cells. Furthermore, cHBIs demonstrated in vivo inhibition 
of allergic responses in both murine models. We establish the cHBI design to be a versatile 
platform for inhibiting hapten/IgE interactions, which can potentially be applied to inhibit IgE 
mediated allergic reactions to any drug/small molecule allergy.
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Immediate immunoglobulin E (IgE) mediated hypersensitivity reactions caused by drugs 
(drug allergies) are a type of adverse drug reaction (ADR) that afflicts over 2 million people 
per year in the US and can trigger severe and life-threating anaphylaxis.(1) Drug allergies 
are unpredictable, can occur to very commonly used antibiotics such as sulfa drugs and 
penicillins, and currently have no preventative therapies.(2) In light of this need, here we 
present the development of a unique allergy inhibitor platform that can be used to prevent 
IgE mediated allergic reactions triggered by small molecule drugs such as penicillin.
Severe drug allergy reactions are due to a process called haptenization in which multiple 
copies of a drug molecule covalently bind to a carrier protein, decorating the protein with 
modified versions of the drug, known as drug-haptens.(2, 3) The multivalently presented 
haptens on the surface of the protein trigger the multivalent crosslinking of drug-hapten 
specific IgE, which are present on the surfaces of mast cells and basophils. These 
crosslinking events then trigger the degranulation of mast cells and basophils. (4, 5)
Among numerous drug allergies, β-lactam antibiotic allergies (e.g. penicillin and penicillin 
derivatives) are of particular concern given their wide usage. β-lactam rings are reactive with 
primary amines and can readily haptenize serum proteins and initiate crosslinking of IgE on 
mast cells and basophils, causing allergic reactions.(6) In this paper, we describe the rational 
design, synthesis and in vitro and in vivo evaluation of a new class of allergy inhibitor 
molecules we call covalent heterobivalent inhibitors (cHBIs) developed to specifically and 
permanently inhibit the binding interactions between drug-haptens and their respective IgE, 
hence inhibiting the allergic response. In this study, we synthesized a cHBI that specifically 
inhibit allergic responses to penicillin G (a β-lactam antibiotic) by covalently binding 
penicillin G specific IgE and thereby preventing degranulation responses. Finally, to 
demonstrate that our platform can be used to develop cHBI inhibitors for a broad class of 
small molecule drugs in addition to penicillin G, we have further validated our approach by 
using another small molecule that is frequently used as a hapten, dansyl.(7)
MATERIALS AND METHODS
Materials:
NovaPEG Rink Amide resin, 5(6)-carboxy-fluorescein, HBTU (2-(1H-Benzotriazole-1-
yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate), Fmoc-Lys(IvDde)-OH, Fmoc-
Arg(pfb)-OH, 10 kDa 0.5 mL centrifugal filters, and BSA were purchased from EMD 
Millipore.
DMF (N,N-Dimethylformamide) (>99.8%), DCM (dichloromethane) (>99.8%), DIEA 
(N,N-Diisopropylethylamine), methanol, hydrazine, piperidine, TFA (trifluoroacetic acid), 
TIS (triisopropylsilane), Tryptamine, 2-Naphthaleneacetic Acid, ethylene diamine, biotin, 
BOC2O (Di-tert-butyl carbonate), DMAP (4-(Dimethylamino)pyridine), Succinic anhydride, 
CS2 (Carbon disulfide), BDI (butane diisthiolcyanate), THF (Tetrahydrafuran), TPP 
(triphenylphosphine), DIAD (diisopropylazocarboxylate), MeI (methyl iodine), DNFB (2,4-
Dinitro-1-fluorobenzene), acetonitrile, acetic acid, methanol, carbonate-bicarbonate buffer, 
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Tween 20, IBA (Indole-3-butyric acid),Biotin and PBS (phosphate buffered saline), 
Bicarbonate-carbonate buffer (Bicarb), OVA (ovalbumin), Step-HRP (streptavidin 
conjugated to HRP), PCMB (p-chloromercuribenzoic acid) were purchased from Sigma 
Aldrich.
High Binding and Non-Binding 96 well plates were purchased from Corning. Minimum 
Essential Media, Penicillin-Strep solution, L-glutamine, and Amplex Red ELISA kits were 
purchased from Life Technologies. Bovine Serum Albumin was purchased from Gemini 
Biosciences. 96 well Tissue Culture plates were purchased from Falcon. EG2 (Fmoc-N-
amido-dPEG2-acid) and EG8 (Fmoc-N-amido-dPEG8-acid) were purchased from Quanta 
biodesign. FITC (Fluorescein Isothiocyanate) was purchased from Toronto Research 
Chemistry. Anti-dansyl IgE (clone 27-74) and anti-human cyclinA IgE (clone BF683) were 
purchased from BD Biosciences. Mouse IgGPenicillin (monoclonal antibody clone P2B9) was 
purchased from Abcam Anti-DNP IgE (clone SPE-7) was purchased from Sigma Aldrich.
Synthesis of Inhibitors and Ligands
Molecules were synthesized using solid phase peptide synthesis as described previously(8) 
with several modifications. See supplemental figure S-2 and S-3 for further details.
The following molecules used in this study were analyzed using high resolution mass 
spectroscopy using Bruker microTOF II mass spectrometer. Note that all molecular weights 
have +1 mass increase from addition of a proton. cHBIdansyl (C63H94N8O17S2) was 
determined to be 1299.61 Da (1298.62 Da expected); HBIdansyl (C49H71 N5O12S) was 
determined to be 970.20 Da (969.19 Da expected); cHBIPen (C85H135 N17O22S3)was 
determined to be 1842.92 Da (1841.91 Da expected); HBIBPO (C78H115 N13O25S) was 
determined to be 1666.71 Da (1665.70 Da expected); Pen (C41H58 N10O14S) was 
determined to be 947.39 Da (946.39 Da expected); Biotin-cHBIdansyl (C86H133 N13O23S3) 
was determined to be 1812.87 Da (1811.88 Da expected); Biotin-cHBIPen (C102H162 
N18O27S4) was determined to be 2201.08 Da (expected 2200.07 Da); FITC-cHBIdansyl 
(C104H142 N12O30S2) was determined to be 2104.96 Da (expected 2103.94 Da) cHBIDNP 
(C62H92 N10O22S) was determined to be 1361.62 Da (expected 1360.61 Da); Dansyl-ITC 
(C53H88 N8O17S2) was determined to be 1174.46 Da (expected 1173.45 Da).
In Solution Conjugation of cHBI Molecules
Before ELISA analysis of cHBI-antibody conjugates, we performed an in-solution-
conjugation of cHBI molecules and antibodies allowing ITC moieties to react with primary 
amines on antibody proteins. cHBIPen or cHBIdansyl at various concentrations were 
incubated with either IgEdansyl or IgEDNP (as a control) or IgGPen or BSA (as a control) at 1 
μM concentrations for various incubation times in either PBS (pH 7.4) or Bicarbonate-
Carbonate Buffer (pH 9.6) at 50 μL total volumes at 37ºC. Note that IgGPen was used due to 
the lack of commercially avaliable Pen specific IgE. Additionally, IgGPen is specific for 
Penicillin G with an intact beta-lactam ring, not penicilloyl, which explains the lower 
affinity it has for penicilloyl displaying molecules. After reaction, excess cHBI molecules 
were removed using membrane filtration with 10 kDa 0.5 mL Centrifugal Filters (Millipore) 
by washing antibodies three times in PBS. Purified antibodies were analyzed with a 
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SpectraMax M5 spectrophotometer at 280 nm using an extinction coefficient of 200,000 cm
−1 M−1 for IgEDNP and IgEdansyl and 150,000 cm−1 M−1 for IgGPen.
Synthesis of BSA and OVA drug-hapten conjugates
Protein-Hapten conjugates were prepared in order to sensitize mice for allergen challenges 
and to trigger in vitro degranulation as previously described with some modification.(9) Two 
different haptens, penicillin and dansyl chloride, were used with two different protein 
carriers, OVA and BSA. OVA conjugates were injected into mice to sensitize animals (see in 
vivo method section) while BSA conjugates were used to trigger degranulation and perform 
allergen challenges. Dansyl was conjugated to OVA and BSA by dissolving 20 mg of BSA 
or OVA in 3 mL bicarbonate-carbonate buffer (pH 9.6) and then adding 20 mg of dansyl 
chloride that was dissolved in DMF. These compounds reacted under mild stirring over 24 
hours at 37ºC. After reaction, products were passed through a 0.22 μM filter and filtered 
using a 10 kDa membrane filtration to remove excess dansyl. Protein concentration and 
hapten labeling was determined using a dansyl extinction coefficient of 3400 cm−1 M−1 at 
335 nm, and an extinction coefficient of 43800 and 30950 cm−1 M−1 at 280 nm for BSA and 
OVA respectively and a dansyl correction factor of 0.39 to correct for dansyl absorbance at 
280 nm. Using the ratios of absorbance at 335/280 nm, we determined dansyl-BSA to have 
18 dansyl per protein and dansyl-OVA to have 12 dansyl per protein.
For penicillin conjugates, we performed a similar addition of hapten to protein, except using 
200 mg of penicillin G salt and allowing reaction to take place over 72 hours. Pen-protein 
conjugates were filtered in a similar manner. In order to determine conjugation efficiency, 
we used a penmaldate assay from Levine et. al.(6) We determined Pen-BSA to have 12 Pen 
groups per protein while Pen-OVA had 8 Pen groups per protein.
Fluorescence Quenching
Briefly, 200 μL of 40 nM dilutions of either IgEdansyl or IgGPen were placed in a 96 well 
non-binding plate. DNP labeled molecules were then titrated into wells and fluorescence 
(Ex. 280, Em. 335) was read using a SpectraMax M5 spectrophotometer. As molecules 
bound their respective antibodies, DNP quenched the fluorescence of tryptophan on 
antibodies. The drop in fluorescence was compared to a PBS control and a control with 
tryptamine diluted to the same initial fluorescence value as the antibody dilutions.
ELISA Assay
Binding of cHBI molecules to antibodies was observed using a direct ELISA. Prior to 
ELISA test, antibodies or BSA were incubated at 100 nM concentrations with biotin labeled 
cHBI molecules at various concentrations in PBS at 37ºC for 5 hours, then unbound cHBI 
was removed using membrane filtration with a 10 kDa molecular weight cutoff (Thermo 
Scientific). After filtration, protein concentration was determined by absorbance, using ε= 
200,000 cm−1 M−1 for IgE and 150,000 for IgG and 40,900 for 43,820 for BSA at 280 nm. 
100 μL of 2 nM antibody or BSA molecules previously reacted with cHBIs that were labeled 
with biotin were incubated for 2 hours in bicarbonate buffer on a high binding 96 well plate. 
Plates were washed with an AquaMax 2000 plate-washer to remove unbound antibody. 
Wells were blocked with a 5% BSA, 0.2% Tween 20 solution in PBS for 1 hour, washed and 
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incubated with an streptavidin conjugated to HRP for 1 hour in blocking buffer. Plate was 
washed again and an Amplex Red Kit was used to quantify ELISA signal using a 
SpectraMax M5 spectrophotometer according to manufacturer’s instruction.
Flow Cytometry
Flow cytometry was performed on RBL-2H3 cells using a Guava easyCyte 8HT in order to 
demonstrate dansyl cHBI molecule attachment under more physiological conditions. 
RBL-2H3 cells split at 500,000 cells per mL into a 24 well dish (0.5 mL each) and allowed 
to attach to plate overnight. Following morning, 0.5 μg of IgEDNP or IgEdansyl was added 
and allowed to incubate for 24 hours. Cells were then washed twice with sterile PBS, and 
incubated with fresh media with FITC- cHBIdansyl between 0-1000 nM for 16 hours. Cells 
were then washed again with PBS and given fresh media, then chilled on ice for 30 minutes. 
Cells were washed with PBS and incubated in 1.5% BSA in PBS, scraped, and analyzed.
Tissue Culture and Degranulation assays
RBL-2H3 cells were every 48-72 hours at a 1:3 dilution into fresh RBL-2H3 media. Plates 
for experiments were prepared at roughly 500,000 cells per mL in either 0.5 mL or 100 μL 
wells on tissue culture plates. Degranulation assays were performed with some 
modifications based on a procedure in Handlogten et al.(9) All of these degranulation assays 
followed this basic procedure: (1) RBL cells previously primed with IgE (either from 
monoclonal sources or mouse sera from mouse sensitization below) were incubated with 
cHBIs for varying amounts of time, (2) cells were washed to remove any unbound or 
unconjugated cHBIs, (3) allergen was added to stimulate degranulation. Briefly, 50,000 cells 
were incubated in a 96 well tissue culture plate and either mixtures of monoclonal antibodies 
(with 25% IgEdansyl and 75% orthogonal IgEcyclinA) to a final concentration of 1 μg/mL or 
dilutions of mouse sera were added for 24 hours. Cells were then washed with sterile PBS 
and cHBI compounds were added at various dilutions for varying time points. Cells were 
then washed with tyrodes buffer and degranulation was triggered using either dansyl-BSA or 
Pen-BSA as previously described.(9) Percent inhibition was calculated by dividing percent 
degranulation with cHBI’s by control without cHBI for same allergen concentration. For 
experiments in figure 4C, after incubating with inhibitors for 24 hours, cells were washed 
and allowed to incubate in cell culture media between 24-72 hours before testing 
degranulation response.
In vivo experiments
Balb/c female mice (7–8 wk) were obtained from Harlan Biosciences (Indianapolis, IN). 
Balb/c mice were chosen due to their marked increase in IgE mediated mast cell responses.
(10) Mice were maintained in pathogen-free conditions, and studies were approved by the 
Indiana University Institutional Animal Care and Use Committee. All control mice were co-
housed with experimental mice.
Ear Swelling Murine Model
Mice were sensitized using haptenized OVA proteins as previously described(8), except 
using dansyl-OVA or Pen-OVA as the sensitizing agent. Mice were injected by i.p. on days 1 
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and 7 with 20 μg of haptenized OVA. On day 14, mice were challenged via intradermal 
injection with 20 μg of hapten-BSA conjugates in one ear with a PBS control in the other 
ear, and ear swelling was measured and expressed as a change before and after allergen 
challenge. Ear tissue was collected 2 h after challenge for histological examination.(8) Mice 
were injected by i.v. with cHBI molecules either, 16 hours or simultaneously with hapten-
BSA challenge (i.e. co-administered with hapten-BSA).
Murine Anaphylaxis Model
For the systemic anaphylaxis model,(11) mice were sensitized with 20 μg Pen-OVA 
adsorbed to alum i.p. on day 0 and 7. Subsequently, 100 μg Pen-BSA was used to challenge 
mice i.p. on day 14. Inhibitor (10nM) or PBS was injected via i.v one hour before challenge. 
Data is combined from two independent experiment (n = 6 for PBS treated and n = 9 for 
cHBI treated). No difference was observed between animals treated with 10nM of cHBIPen 
and PBS (data not shown).
Ear histological analysis
Ear biopsies from mice were fixed in 10% formalin for 24 h and then transferred to 70% 
Ethanol. Ears were paraffin embedded, and 5-μm sections of whole ears were stained with 
H&E. Routine histological techniques were used to paraffin embed ears, and 5-μm sections 
of whole ears were stained with H&E. Quantitative digital morphometric analysis of ear 
thickness was performed using the application program ImageJ. A minimum of 4 
measurements were analyzed. The same area for each ear was captured, and dermal 
thickness was calculated in inches per pixel.
Statistics
Statistical significance was determined using a student’s t test. A p value ≤ 0.05 was 
considered statistically significant. Calculations were performed using the Prism 6.0 
software program.
RESULTS
Design of Covalent Heterobivalent Inhibitor (cHBI)
In this study, we engineered cHBI (Figure 1A) to inhibit mast cell degranulation by 
irreversibly inhibiting the binding interactions between drug-hapten specific antibody and 
the haptenized-drug molecules, thereby inhibiting drug allergy reactions. The cHBI design 
has three components: i) a drug-hapten used to target the antigen binding site (ABS), ii) a 
small molecule ligand to target the nucleotide binding site (NBS), and iii) reactive functional 
group (RFG) to form irreversible covalent bonds with the target IgE (Figure 1A). The NBS 
is an underutilized conserved binding site located proximal to the ABS between the heavy 
and light chain of all immunoglobulins (Figure 1B).(8, 12) In our laboratory, we have 
identified several small molecule ligands, including indole-3 butyric acid (IBA) and 2-
naphteleneacetic acid (Napht), that specifically bind the NBS with low micromolar affinities.
(13-17) The cHBI is designed to first associate bivalently to the allergen specific IgE via 
ABS and NBS sites, followed by a covalent reaction with the proximal lysine residues via 
RFG, irreversibly preventing allergen/IgE interactions (Figure 1C).
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NBS ligand and Hapten selection for the cHBIs
To aid in the development cHBIs as inhibitors for penicillin drug allergies by screening 
potential ABS and NBS ligands, we first evaluated the inhibitors that lacked the covalently 
reactive RFG moiety (HBI). The HBIs were designed to simultaneously target the NBS and 
ABS of penicillin specific IgE (IgEPen) in a heterobivalent fashion, but without the ability to 
form covalent bonds, their complexes with IgE eventually dissociated.(9) After screening a 
library of potential NBS targeting compounds, we selected 2-naphteleneacetic acid (Napht) 
as the NBS ligand with a 1.8±0.3 μM Kd for IgE by fluorescence quenching experiments 
(Figure 2A).
As the ABS targeting ligand in our design, we incorporated a drug-hapten moiety derived 
from penicillin G. It is important to note while frequently described as an allergy to 
penicillin G, the actual drug-hapten, which binds IgE, is a conjugate of penicillin G with a 
primary amine, forming a benzylpenicilloyl (Pen) group (Figure 2B). Hence, in our studies 
we used Pen to target the ABS of IgEPen. Due to commercial or otherwise unavailability of 
IgEPen, we used a monoclonal penicillin G specific IgG (IgGPen) antibody to measure 
binding constants of the penicillin-based molecules. We first measured the Kd of Pen for 
IgGPen to be 20±4 μM by fluorescence quenching (Figure 2B). Next, we synthesized 
heterobivalent molecules that displayed Pen and an NBS ligand (HBIPen, see methods for 
further details on HBI synthesis). The structure of HBIPen is given in Table 1. We 
determined the binding of HBIPen to IgGPen to be 0.96±0.11 μM, an over 20 fold 
improvement over monovalent Pen binding to IgGPen alone (Figure 2B). Furthermore, we 
synthesized a HBI with a similar design using dansyl as the ABS ligand and Napth as the 
NBS ligand (HBIdansyl; Table 1). We then measured the binding affinity of HBIdansyl to an 
anti-dansyl IgE (IgEdansyl) using fluorescence quenching and calculated a nearly 5-fold 
increase in observed Kd for HBIdansyl (6.4±2.5 nM) over monovalent dansyl (29.9±10 nM) 
(Figure 2C). Combined, the HBIPen and HBIDansyl binding studies demonstrated how 
heterobivalent binding of the HBIs to the target antibodies improves the overall inhibitor 
avidity, while maintaining specificity.
Reactive Functional Group (RFG) selection
In addition to NBS and ABS ligands, the most critical design factor for the cHBI is the 
presence of a RFG that can form covalent bonds after cHBI non-covalently binds to the 
target IgE, thereby permanently inhibiting IgE/allergen interactions through covalent 
inhibition. One of the major challenges of covalent inhibitors is that the RFG must bind 
rapidly but only with intended targets and without significant levels of off target conjugation. 
We have chosen an amine reactive chemical moiety, isothiocynate (ITC), as the RFG in the 
cHBIs design (Figure 2D). ITC compounds are frequently found in nature and are reportedly 
nontoxic.(18-20) ITC groups form thiourea bonds with primary amines, such as lysines, in 
elevated pH solutions (>9) but react rather slowly under physiological pH (7.4), having an in 
vivo half-life of over 50 hours.(21, 22) Since the ITC functionalities typically have fairly 
slow reaction kinetics under physiological conditions, the pre-association with the ABS and 
the NBS sites is necessary to increase the effective molarity of ITC for the proximal lysine 
residues, which in turn enhances the kinetics and specificity of covalent bond formation. As 
shown in Figure 2D, we predict that allergen specific IgE inhibition via cHBIs is a three step 
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process. First, a monovalent binding interaction by either the hapten or NBS ligand forms 
with the target IgE, followed by the second binding event which results in the stable 
heterobivalent cHBI-IgE complex. Finally, because the resulting complex provides an 
increased effective molarity for the ITC moiety to the lysine located in proximity to the 
NBS, formation of the covalent bond is expedited. We have assessed the crystal structures of 
several antibodies and observed at least one potential lysine within 2 nm of the lip of the 
NBS pocket in each case (Figure S-1). We envisioned cHBIs armed with these design 
parameters to provide selective and potent inhibition of target IgE-allergen interactions. 
Hence, we synthesized cHBIs specific to Pen (cHBIPen) or dansyl (cHBIdansyl) (Table 1) to 
test our hypothesis (see methods and supplementary figure 2 and 3 for further detail on 
chemical synthesis).
cHBIs Bind to the Target IgE Specifically and Form Irreversible Bonds
After synthesizing cHBIs, we evaluated their ability to form covalent bonds specifically with 
their target IgE. In order to quantify conjugation of cHBI molecules to the antibodies, cHBIs 
were synthesized with biotin tags and their conjugation to the target antibody was measured. 
Specifically, we incubated IgGPen with a biotin tagged cHBIPen (Biotin-cHBIPen) for 16 
hours at 37º, removed unbound Biotin-cHBIPen via membrane filtration and then measured 
modified IgGPen via ELISA (Figure 3A). The fluorescence increased in a concentration 
dependent manner between 1 nM and 100 nM of cHBIPen while conjugation to a BSA 
control remained minimal, demonstrating the specificity of cHBIPen (Figure 3A). Similar 
results were observed using dansyl and a biotinylated cHBIdansyl (Biotin-cHBIdansyl, Figure 
3B).
Finally, we validated that the specific binding and conjugation of the cHBIs to the IgE can 
also occur in a relevant cellular assay system in a crude biological mixture such as cell 
culture media containing fetal bovine serum (10%). For this, rat basophilic leukemia (RBL) 
cells were primed with IgEdansyl to allow for binding of the IgE to the RBL FcεRI cell 
surface receptors. Next, the RBL cells were incubated with FITC-cHBIdansyl (cHBIdansyl 
synthesized with a fluorescein tag). Binding of FITC-cHBIdansyl to IgEdansyl on the cell 
surface was analyzed with flow cytometry. The data indicated that cHBIdansyl molecules 
bind effectively to IgEdansyl on the surfaces of RBL cells in a dose dependent manner 
(Figure 3C). Negative control experiments where RBL-2H3 cells were primed with IgEDNP 
showed significantly less binding at these concentrations (Figure 3C, p<0.005). Taken 
together, these results validate that cHBIs covalently and specifically bind to membrane 
bound target IgE in cellular assays.
cHBIs Demonstrate Inhibition of Degranulation in Cellular Assays
After confirming that cHBI molecules form specific covalent bonds with their target 
antibodies, next, we evaluated the ability of cHBI to inhibit mast cell degranulation in 
cellular assays. We tested the cHBIs with a modified version of a well-established 
degranulation assay using RBL cells where cHBIs are incubated with primed RBL cells, 
washed to remove any unconjugated inhibitor and then challenged with a haptenized BSA 
protein (dansyl-BSA).(23, 24) As demonstrated in figure 3D, when cHBIdansyl (1 μM) was 
incubated with IgEdansyl primed RBL cells, degranulation responses were completely 
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inhibited over a wide range of allergen concentration (dansyl-BSA: 0.01 ng/mL- 2 μg/mL). 
Similar control experiments were performed where RBL cells were primed with IgEdansyl 
and then incubated with cHBIDNP (a cHBI with a different small molecule specificity) did 
not yield any inhibition when cells were challenged with dansyl-BSA, verifying the 
specificity of these inhibitors (Figure 3D). Additional control experiments were also 
performed where cHBIdansyl was synthesized omitting one or two of the three moieties of 
the cHBI design (NBS ligand, hapten or ITC). In these experiments, we observed significant 
decrease in inhibition of degranulation when any of one the three moieties were absent from 
the cHBI design (Figure S-4A).
We further tested the effects of varying incubation times and concentrations of cHBIdansyl 
(Figure 3E). As shown in Figure 3E, inhibition of degranulation increased with increasing 
concentrations of cHBIdansyl and with increasing incubation times. At doses near 1000 nM, 
>50% inhibition was observed in as short as a 10 minute incubation time and >95% 
inhibition was observed after a 1.5 hour cHBI incubation at the same 1000 nM dose, which 
we expect to correspond to a clinically feasible milligram scale dose, although further 
pharmacokinetic data is required to verify this (Figure 3E).(25) Next, we tested if cHBI 
demonstrated long lasting inhibitory effects in cellular assays, given that they were designed 
as irreversible inhibitors. Primed RBL cells were incubated with cHBIdansyl for 16 hours as 
before, but after washing away the unbound cHBIdansyl, cells were incubated in cell culture 
media for 24-72 hours before being challenged with dansyl-BSA. As demonstrated in figure 
3F, cHBIdansyl was a potent inhibitor even after 72 hours of incubation, due to the formation 
of irreversible covalent bond between cHBI and target IgE.
cHBIs Inhibit Degranulation in RBL cells primed with Mouse Sera
In order to further evaluate cHBIs in a more physiologically relevant system, we primed 
RBL cells with serum from mice challenged with penicillin haptenized ovalbumin protein 
(Pen-OVA). Briefly, mice were sensitized with two i.p. injections of 20 μg Pen-OVA at one-
week intervals (on day 1 and day 7) in order to generate a polyclonal population of IgE 
antibodies specific to Pen (IgEPen). On day 14, sera were pooled from five mice. Before 
performing experiments with cHBIs, we first confirmed the presence of IgEPen in the serum 
and that this response is IgE mediated (Figure S-4B). Next, RBL cells were incubated in a 
90/10% mixture of cell culture media to Pen-OVA sensitized mouse serum overnight, 
washed and tested using an RBL cell assay. Cells incubated with cHBIPen had a significant 
inhibition of degranulation at all concentrations of Pen-BSA challenge (p <10−4, Figure 4A). 
In a separate experiment, RBL cells were primed with Pen-OVA sensitized serum containing 
IgEPen, washed and then incubated with varying concentrations of cHBIPen and challenged 
with 200 ng/mL Pen-BSA. As demonstrated by figure 4B, cHBIPen significantly inhibited 
degranulation at 100 nM of cHBIPen and inhibited over 75% of degranulation responses at 
200 nM (p<0.01). One plausible explanation for why cHBIPen did not completely eliminate 
degranulation is that IgE specific to other minor determinants (other than benzyl penicilloyl) 
of penicillin G were generated when the mice were sensitized.(26) These two experiments 
were also repeated using dansyl, priming RBL cells with mouse serum sensitized with 
dansyl-OVA, incubating the cells with cHBIdansyl and challenging them with dansyl-BSA. 
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Inhibition of degranulation was observed at all concentrations of dansyl-BSA and cHBIdansyl 
(Figure 4C, 4D).
cHBIs Inhibit Degranulation in Vivo
After the ex vivo validation of cHBIs, we tested their inhibitory potential in vivo using a 
mouse allergy model. Mice were sensitized with Pen-OVA on day 1 and 7 to allow for 
IgEPen development. On day 14, mice (5 mice per group) were challenged with 20 μg of 
Pen-BSA in the presence or absence of cHBIPen via injection into the ear. An additional 
group of control mice were injected with PBS in place of Pen-BSA. The allergic response 
was monitored by measuring ear swelling 2 hours after challenge. As demonstrated in figure 
5A, Pen-OVA sensitized mice that were co-administered with 1 nmol or 10 nmol of cHBIPen 
during Pen-BSA allergen challenge demonstrated a significant reduction in ear swelling 
when compared to a control with no cHBIPen injection(p<0.01, Figure 5A). 
Histopathological analysis confirmed an increase in dermal and intradermal tissue thickness 
for mice challenged without cHBIPen when compared to mice injected with either 1 or 10 
nmol per mouse (Figure 5B, Figure S-4C). Mice were also sensitized with dansyl-OVA in a 
similar fashion, and we observed a significant decrease in ear swelling using 1 nmols of 
cHBIdansyl further demonstrating the inhibitory potential of cHBIs (p<0.05, Figure 5C). This 
was also confirmed with histological analysis (Figure 5D, Figure S-4C). However, the 
inhibitory effect of cHBIdansyl did not persist at the 10 nmol dose. We speculate that this is 
an artifact of our experimental design. We coadministered the cHBIdansyl and dansyl-BSA, 
mixing them in the same syringe at very high (0.1 mM) concentrations, likely allowing the 
cHBI to react non-specifically with dansyl-BSA and further labeling the dansyl-BSA with 
dansyl groups, while depleting the cHBIdansyl. We further speculate that this was not the 
case with cHBIPen as penicillin is significantly less hydrophobic than dansyl, leading to 
fewer non-specific interactions.
Next, we tested if cHBIs demonstrated long lasting inhibitory effects in vivo. Pen-OVA 
sensitized mice (N=5) were injected with 1 nmol of cHBIPen and then challenged with Pen-
BSA, either immediately or after 16 hours. At both time points, mice injected with cHBIPen 
retained their resistance to allergic reactions as shown by a significant drop in ear swelling 
when compared to control mice without the inhibitors (p <0.05, Figure 5E).
Finally, cHBIs were evaluated with a murine systemic anaphylaxis model.(11) Mice were 
sensitized as before with Pen-OVA, injected via i.v with 10 nMols of cHBIPen, then 
challenged with i.p. administration of 100μg of Pen-BSA 1 hour after cHBIPen injection and 
their temperature monitored with a rectal probe. The change in body temperature for these 
mice was monitored over the course of two hours after allergen exposure. The no inhibitor 
control group (N=6) experienced a severe drop in body temperature, indicating anaphylaxis, 
while cHBIPen injected mice (N=9) had a significantly smaller change in body temperature 
at 20, 30, 45, 60, 90 and 120 mins (Figure 5F, p<0.05). We calculated the area under the 
curve (AUC) for the data in figure 6F for both cHBIPen treated mice and the control group 
and calculated a significantly smaller absolute value of AUC for cHBIPen treated mice 
(Figure 5G, p<0.05). Furthermore, as seen in Figure 5H, there was a significant drop in 
plasma IL-6 concentration for cHBIPen treated mice compared to the no inhibitor control 
Deak et al. Page 10













group, indicating a reduction in systemic inflammation. Altogether, these results 
demonstrate that cHBIs can block active allergic responses in vivo and have promising 
clinical potential.
DISCUSSION
In this study, we described the design, synthesis and characterization of cHBI, a novel and 
multifaceted inhibitor of drug–hapten and IgE interactions that has promising prospect as a 
therapy for drug allergies. cHBIs were rationally designed to irreversibly inhibit the binding 
interactions between the drug-hapten and its specific IgE of the major allergy determinant, 
thereby effectively and specifically preventing allergic reactions.
We have shown the synthesis and characterization of cHBIs with two distinct specificities: i) 
cHBIPen to inhibit allergic reactions against penicillin G, and ii) cHBIdansyl to inhibit allergic 
reactions to a yet another small molecule, dansyl, in order to demonstrate the broad 
applicability of the cHBI design to any small molecule drug allergy. Each chemical moiety 
in the cHBI design was carefully chosen to facilitate specific inhibition of drug-hapten/
antibody interaction with minimal off target effects. Here, we established that cHBIs 
specifically and irreversibly bound target antibodies while having minimal off target 
interactions with non-specific antibodies or other proteins. Importantly, in a physiologically 
relevant in vitro allergy model, cHBIs irreversibly bound to cell surface-bound IgE, thereby 
preventing degranulation from RBL cells.
Before we started the experiments, one potential concern was related to sequestration of 
cHBI by allergen specific IgG in vivo, making it unavailable to inhibit specific IgE. Since 
cHBI is designed to recognize the Fab and not discriminate by Fc region, it can target all 
antibody isotypes, and not only the IgE (Figure 2A and 3A). Our results, however, 
established that any binding to other isotypes did not diminish anaphylaxis-blocking activity 
in vitro and in vivo experiments. During in vitro experiments, we demonstrated that cHBIs 
effectively inhibited degranulation where RBL cells were primed with serum taken from 
mice sensitized to either Pen or dansyl (which contained a polyclonal antibody mixture to 
the drug-hapten) and then challenged with drug-haptenized proteins. Although these in vitro 
results are impressive, the model cell line used (RBL), while useful for reproducibility of 
experiments across multiple experiments, cannot recapitulate the complexity of mast cell 
responses in vivo. Rather than use more sophisticated cell culture models, such as bone 
marrow derived mast cells, we opted to directly assess cHBI effectiveness using mouse 
models. We performed an extensive in vivo evaluation of cHBIs using two distinct murine 
models. These results demonstrated that the concentration of cHBI was sufficient to bind 
sIgE and prevent allergic responses even when IgG was present. While these studies were 
performed exclusively in mice, we expect similar effects in humans due to the conserved 
nature of IgE and the NBS.(9)
Another concern for this study was the fact that we designed cHBIs to target only the well-
known major determinant of the penicillin allergy, while not taking minor allergy 
determinants into account. Although literature reports have shown SPT reactions to minor 
penicillin allergy determinants, our results established that a single cHBI can still be 
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effective in mice.(27) We believe this is due to the high degree of homology between the 
major penicillin determinant, penicilloyl, and minor determinants such as penicilloate and 
penilloate and the high cross reactivity between beta-lactam antibotics.(28, 29) 
Consequently, all IgE is expected to adopt a moderate binding affinity toward penicilloyl, 
which results in cHBIPen achieving a level of inhibition for these antibodies. This point is 
demonstrated in figure 2B, where incorporating penicilloyl in the bivalent design of HBIPen 
improved the anti-penicillin IgG’s moderately low affinity of 20 μM by 20 fold to 1 μM, due 
to avidity. Additionally, covalent conjugation was achieved at nanomolar concentrations of 
cHBIPen with the same anti-penicillin IgG, suggesting that cHBIs can still covalently bind 
and inhibit minor determinant-specific IgE that has relatively low affinity (Figure 3A). 
Furthermore, it is important to emphasize that the versatile cHBI platform can accommodate 
any number of potential ABS ligands in separate designs, as demonstrated by DNP and 
dansyl examples, and cHBIs specific for the minor determinant sIgE can be easily generated.
This study is particularly significant because it is (1) the first successful design of an 
inhibitor that inhibits specific IgE/allergen interactions and (2) a potential therapeutic for a 
clinically relevant drug allergy. Currently, the only FDA approved IgE inhibitor is the 
monoclonal antibody omalizumab, which is pan-specific for all IgE and has only been 
approved for use in chronic asthmatic conditions and chronic idiopathic urticaria.(30, 31) 
Additionally, omalizumab has been linked to a trend in cardiac toxicity and increased risk of 
parasitic infections, presumably due to its non-specific targeting of all IgE.(32, 33) We 
anticipate that the cHBIs, due to their allergen selective design and controlled covalent 
inhibition, have the potential to overcome these issues in the clinic.
We anticipate that cHBIPen will be long lasting as its inhibitory characteristics (due to 
irreversible covalent bonds) should persist throughout the course of a mast cell or basophil 
IgE lifetime, which would be ideal for clinical use. However, longer term use studies would 
be necessary to confirm this, as inhibition up to only 16 hours was tested in vivo. 
Additionally, there is a concern that cHBIs could affect the normal immunological functions 
of immunoglobulins after long term use. While we show little off target antibody binding, it 
would be crucial to track long term off target cHBI binding in vivo for future studies. 
Another potential usage for cHBIs would be for aiding in drug desensitization. Rapid drug 
desensitization is an effective technique for reducing allergic reactions to a drug in the short 
term. (34, 35) cHBIs could be utilized to improve the effectiveness of this technique by 
reducing the allergic side effects. Finally, this study obtained similarly promising results 
with a different small molecule-hapten, dansyl, which demonstrates that the cHBI design can 
be used to develop inhibitors to any small molecule drug compound such as other penicillin 
derivatives, sulfa drugs or chemotherapeutics.
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• cHBIs display a drug metabolite, an antibody targeting moiety and a reactive 
group
• cHBI specifically target drug allergy IgE and prevent drug induced 
degranulation
• cHBIs to penicillin were synthesized and prevent penicillin allergies in vivo.
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Covalent Heterobivalent Inhibitor (cHBI) molecular design and mechanism of action. (A) 
Schematic illustration of cHBI structure with its three major components: Antigen binding 
site (ABS) targeting ligand (drug-hapten), nucleotide binding site (NBS) ligand, and 
chemically reactive functional group (RFG) to enable irreversible covalent bond formation 
(B) A crystal structure of an immunoglobulin (PDB: 1IGY) demonstrating the location of 
the NBS (with NBS residues colored in green) between the heavy chain (in blue) and light 
chain (in red) is shown. Schematic of cHBI binding to the antibody via the NBS and ABS is 
also shown. (C) Schematic illustration of the cHBIs inhibiting allergen-IgE interactions. 
Without cHBI (as seen in the top), haptenized-drug multivalently crosslinks drug-hapten 
specific IgE bound to mast cells, triggering degranulation. In the presence of cHBIs 
(bottom), the binding of the haptenized-drug to the IgE is inhibited, thereby preventing 
crosslinking and degranulation.
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Chemical Design of Covalent Heterobivalent Inhibitors (cHBI) and IgE-binding studies. (A) 
Structure of Naphthaleneacetic acid (Napht) as an NBS ligand is shown. The binding of 
Napht to IgE antibody was determined by fluorescence quenching experiments (Kd = 1.8 
μM). (B) Structure of Benzylpenicilloyl (Pen), the most common penicillin hapten, is shown. 
The binding of Pen to IgGPen and the binding of the heterobivalent inhibitor engineered to 
inhibit Pen- IgGPen interactions (HBIPen) are shown. Binding was measured by 
fluorescence quenching experiments (Kd(Pen)= 20±4 μM, Kd(HBIPen)= 0.96±0.11 μM) (C) 
Structure of dansyl and binding of both monovalent dansyl (dansyl) and the engineered 
heterobivalent dansyl (HBIdansyl) to IgEdansyl is shown. Binding was observed through 
florescence quenching experiments (Kd(dansyl)= 29.9±10 nM, Kd(HBIdansyl)= 6.4±2.5 
nM). Error bars represent ±SD of technical triplicate experiments. (D) Crystal structure of a 
typical antibody binding pocket with cartoon depicting the cHBI covalent binding to 
antibodies. First, cHBIs bind hetero-bivalently to the target antibody via its ABS and NBS 
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targeting domain with enhanced avidity. Next, cHBIs react covalently with the lysine side 
chains proximal to the NBS via its RFG (the ITC moiety) forming an irreversible bond.
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cHBI molecules bind and inhibit target IgE in vitro and in cellular assays. (A) Biotin-
cHBIPen selectively binds to an IgGPen (black bars). Only negligible binding was observed 
with a BSA control (dashed bars). IgGPen or BSA was incubated for 16 hours at 37ºC with 
Biotin-cHBIPen, purified with membrane filtration to remove unbound cHBI, and binding 
was monitored by measuring fluorescence from an Amplex red substrate after reaction with 
streptavidin-HRP conjugate in an ELISA assay. (B) Biotin-cHBIdansyl binds to IgEdansyl. 
Only negligible binding was observed to IgEDNP which was used as isotype control (dashed 
bars). IgEdansyl or IgEDNP was incubated for 16 hours at 37ºC with Biotin-cHBIdansyl, 
purified with membrane filtration to remove unbound cHBI, and binding was monitored by 
measuring fluorescence from an Amplex red substrate after reaction with streptavidin-HRP 
conjugate in an ELISA assay. (C) In a cellular binding assay, FITC-cHBIdansyl selectively 
bind to the IgEdansyl present on the surface of RBL-2H3 cells. RBL-2H3 cells were primed 
with IgEdansyl and then incubated with FITC-cHBIdansyl, washed and analyzed with flow 
cytometry. As a control, IgEDNP, which targets a different small molecule, was used in 
place of IgEdansyl. All cellular binding experiments were performed on ice. RFU- Relative 
Fluorescence Units. (D) RBL cells were primed with IgEdansyl, and incubated for 5 hours 
with 1μM of cHBIdansyl. Cells were washed to remove unbound inhibitors and were 
challenged with varying concentrations of dansyl haptenized BSA (dansyl-BSA). 
Degranulation was observed using a standard beta-hexoamidase assay. Red points indicate 
cHBIdansyl incubated cells. Control experiments were performed with PBS (blue) or 
cHBIDNP (green) in place of cHBIdansyl. (E) IgEdansyl sensitized RBL cells were incubated 
with cHBIdansyl at various concentrations and for various durations. Cells were washed to 
Deak et al. Page 19













remove unbound inhibitors and were challenged with 100 ng/mL dansyl-BSA. Inhibition of 
degranulation (Inhibition %) when compared to PBS control is shown. (F) RBL cells were 
primed with IgEdansyl and then incubated with cHBIdansyl at varying concentrations for 16 
hours. Cells were washed to remove unbound inhibitors, incubated in cell culture media for 
varying periods of time (0, 24, 48, and 72 h), washed a second time, and then challenged 
with 100 ng/mL dansyl-BSA. Inhibition of degranulation is shown. Data represent the mean 
± SD of biological triplicate experiments.
Deak et al. Page 20














cHBIs inhibit degranulation ex vivo. (A) 5 Balb/c mice were challenged with Pen-OVA. 
Their serum was pooled and then used to sensitize RBL-2H3 cells (in a mixture of 10% 
serum with 90% cell culture media, overnight incubation then washed). RBL-2H3 cells were 
then incubated with 500 nM of cHBIPen (black bar) or with a PBS control (hashed bar) in 
cell culture media overnight. Cells were washed to remove unbound inhibitors and 
challenged with Pen-BSA at varying concentrations. (B) RBL-2H3 cells primed with serum 
from Pen-OVA challenged mice were washed and then incubated with varying 
concentrations of cHBIPen (black bar) overnight, washed again to remove unbound cHBI and 
challenged with 200 ng/mL Pen-BSA. (C) Similarly, 5 Balb/c mice were sensitized with 
dansyl-OVA. Their serum was pooled and then used to prime RBL-2H3 cells. RBL-2H3 
cells were washed and then incubated with 500 nM of cHBIdansyl (black bar) or with a PBS 
control (hashed bar) overnight, washed again to remove unbound inhibitor and challenged 
with dansyl-BSA at varying concentrations. (D) RBL-2H3 cells sensitized with dansyl-OVA 
challenged serum were washed and then incubated with varying concentrations of 
cHBIdansyl (black bar) overnight, washed again to remove unbound cHBI and challenged 
with 2 μg/mL dansyl-BSA. In all experiments, degranulation was observed with a standard 
beta-hexoamidase assay. Data represent the mean ± SD of biological triplicate experiments. 
*indicates p<0.0001
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cHBIs inhibit allergic responses in vivo. (A) Balb/c mice were sensitized twice with two i.p. 
injections of Pen-OVA at 1-wk intervals on day 1 and day 7. On days 14, mice were 
challenged with intradermal injections Pen-BSA in the presence cHBIPen (1nM, N=4, or 10 
nM, N=4) or absence of cHBIPen (no inhibitor, N=5). The control experiment included a 
PBS treatment (N=4) in place of Pen-OVA. (B) Immunohistological images of ear tissue in 
the presence or absence of cHBIPen is shown; the scale bar represents 200 μm. (C) Similarly, 
Balb/c mice were sensitized twice with two i.p. injections of dansyl-OVA on days 1 and 7. 
On day 14, mice were challenged with intradermal injections of dansyl-BSA in the presence 
cHBIdansyl (1nM, N=5, or 10 nM, N=4) or absence of cHBIdansyl (no inhibitor, N=5) as a 
control. (D) Immunohistological images of ear tissue in the presence or absence of 
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cHBIdansyl is shown; the scale bar represents 200 μm. (E) Balb/c mice were sensitized twice 
with two i.p. injections of Pen-OVA at 1-wk intervals on day 1 and day 7. On days 14, mice 
were injected with cHBIPen (1nM) or PBS (no inhibitor) control. The control experiment 
also included a PBS treatment in place of Pen-OVA. Mice were then challenged with 20 μg 
of Pen-BSA either immediately (0 hr) or 16 hours after cHBI injection and ear swelling was 
measured. Data represents mean of 4 or 5 mice per group. (F) cHBIs were tested in a 
systemic anaphylaxis model. Mice were similarly sensitized to Pen-OVA and then injected 
with either 10 nMols of cHBIPen (N=9) or PBS (no inhibitor) (N=6) and then challenged 
with an i.p. injection of 20 μg Pen-BSA one hour later. Temperature drop was then measured 
over the course of 120 minutes. (G) The area under the curve (AUC) for data in part F was 
calculated. (H) IL-6 was measured from mice analyzed with the systemic anaphylaxis 
model. After 120 minutes, mice were sacrificed and their plasma was analyzed via ELISA 
for the presence of IL-6. Error bars indicate ± SEM * p<0.05; ** p<0.01, ****p<0.0001
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Table 1.
List of Compounds Synthesized in this Study- Structures of and molecular weights of heterobivalent 
molecules for penicillin (HBIPen) and dansyl (HBIdansyl), and covalent heterobivalent inhibitors for penicillin 
(cHBIPen) and dansyl (cHBIdansyl) are shown.
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